From: http://www.bizjournals.com/

Let’s say the last time you were paying close attention to what’s going on at local publicly traded biotech firms, it was the Friday before Memorial Day and you were headed to Cape Cod. And let’s say that, at least mentally, you never really left the Cape until this morning.

In today’s roundup of the biggest stock gainers and losers, I have decided to cater to everyone who’s kept half an eye (or less) on the Massachusetts biotech scene over the summer, checking the headlines from an iPad while lying on a beach or alongside the swimming pool.

Since May 23, the Nasdaq Biotechnology index has risen 18 percent, almost four times the Standard & Poor’s 500 Index’s 5.4 percent rise during the same period. The largest three Massachusetts-based biotech firms (Biogen Idec, Vertex Pharmaceuticalsand Alnylam Pharmaceuticals) have all seen their shares shoot up by more than 10 percent. Vertex, in particular, delivered long-awaited trial data from its latest cystic fibrosis drug in development in June, sending its shares soaring.

Of course there were losers, too, mostly among the area’s smaller biotech firms. Sarepta Therapeutics never recovered from a sell-off following updated data from its lead drug for Duchenne muscular dystrophy in July, while BG Medicine’s low revenue for the first half of the year spurred investors to head for the exits.

Here are the summer’s biggest gainers and losers from May 23 through Friday, Aug. 29.

Gainers:

1. OvaScience (Nasdaq: OVAS) rose 89 percent to $13.51.
2. Bluebird bio (Nasdaq: BLUE) rose 78 percent to $40.01
3. Dyax Corp. (Nasdaq: DYAX) rose 55 percent to $10.21.
4. Epizyme (Nasdag: EPZM) rose 50 percent to $34.49.
5. Agios Pharmaceuricals (Nasdaq: AGIO) rose 36 percent to $46.22.

Losers:

1. Aldeyra Therapeutics (Nasdaq: ALDX) fell 49 percent to $3.46.
2. InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) fell 48 percent to $.62.
3. Sarepta Therapeutics (Nasdaq: SRPT) fell 33 percent to $22.93.
4. Genocea Biosciences (Nasdaq: GNCA) fell 32 percent to $12.81.
5. Dicerna Pharmaceuticals (Nasdaq: DRNA) fell 22 percent to $22.28.